These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32807645)

  • 1. Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry.
    Kaplan S; Lee A; Caine N; Charman SC; Bilton D
    J Cyst Fibros; 2021 Mar; 20(2):324-329. PubMed ID: 32807645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
    Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
    Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
    Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Conole D; Keating GM
    Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.
    Schuster A; Haliburn C; Döring G; Goldman MH;
    Thorax; 2013 Apr; 68(4):344-50. PubMed ID: 23135343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
    Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
    Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
    [No Abstract]   [Full Text] [Related]  

  • 10. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
    Uttley L; Harnan S; Cantrell A; Taylor C; Walshaw M; Brownlee K; Tappenden P
    Eur Respir Rev; 2013 Dec; 22(130):476-86. PubMed ID: 24293463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
    Young DC; Zobell JT; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jan; 48(1):1-7. PubMed ID: 22949160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of
    Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
    Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS; Vataire AL; Fukushima A; Aballea S; Khemiri A; Moore C; Medic G; Hemels ME
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
    Dasenbrook EC; Konstan MW; VanDevanter DR
    J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
    Uttley L; Tappenden P
    Curr Opin Pulm Med; 2014 Nov; 20(6):607-12. PubMed ID: 25221853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.